A Phase 3 interventional study of Upadacitinib and Placebo in Spondyloarthritis, sponsored by AbbVie. Completed at 212 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.
Sponsored by AbbVie · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Axial Spondyloarthritis with a site in United States — 7 open to participants now, 9 under way, none of them phase 3. Axial Spondyloarthritis · United States.
Among the 34 studies in Axial Spondyloarthritis with a site in United States, this one is the 3rd largest by enrollment of the 31 interventional ones that give a count, is one of 4 that started in 2019, is one of 13 in phase 3, and was the 21st registered.
186 studies on the registry are indexed under Axial Spondyloarthritis; 56 are open to participants now.
Browse Axial Spondyloarthritis studies →7 of the 34 studies in Axial Spondyloarthritis with a site in United States are open now. Recruiting first, the newest first:
University of Michigan · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
UCB Biopharma SRL · Sites in United States, Bulgaria, Czechia and 3 more countries
Ages 18+
UCB Biopharma SRL · Sites in United States, Canada, Germany and 2 more countries
Ages 18+ · Women only
CARE ARTHRITIS LTD. · Sites in United States, Canada
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Axial Spondyloarthritis studies recruiting now, 20 (53%) set no upper age limit and 12 (32%) stop at 75 or younger; 5 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 734 is above the median of 108 across 122 interventional studies indexed under Axial Spondyloarthritis.
Median enrollment 200 across the 31 interventional studies, 50 across the 3 observational. Of the 21 that completed or were terminated, 17 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 34 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
AbbVie has 9 studies filed under Axial Spondyloarthritis — fewer than ten, so there is no comparison to draw.
4 of the studies in Axial Spondyloarthritis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07836374University of MichiganRENEW Intervention for Axial Spondyloarthritis | 2027-03 |
| NCT07133633Merck Sharp & Dohme LLCA Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013) | 2027-03-29 |
| NCT07642622University of WashingtonPhysical Activity Through Health Technology in Axial Spondyloarthritis | 2027-04 |
| NCT07018206CARE ARTHRITIS LTD.Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis | 2027-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 34 studies in Axial Spondyloarthritis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This protocol includes 2 standalone studies with randomization, data collection, analysis and reporting conducted independently.
The main objectives of this protocol are:
Study 1 (bDMARD-IR AS) is comprised of a 14-week randomized, double-blind, parallel-group, placebo-controlled period (the Double-Blind Period); a 90-week open-label, long-term extension period (the Open-Label Extension Period); and a 30-day Follow-Up Visit (F/U Visit).
Study 2 (nr-axSpA) is comprised of a 52-week randomized, double-blind, parallel-group, placebo-controlled period (the Double-Blind Period); a 52-week open-label, long-term extension period (the Open-Label Extension Period); and a 30-day F/U Visit.
In the Double-Blind Period for both studies, participants are randomized in a 1:1 ratio to receive either upadacitinib or placebo once daily (QD).
Participants in the placebo group switch to upadacitinib 15 mg QD at Week 14 in the Open-Label Extension Period for Study 1 (bDMARD-IR AS) and Week 52 in the Open-Label Extension Period for Study 2 (nr-axSpA).
Participants in remission at Week 104 have the option to enroll in a remission-withdrawal period.
Study M19-944 protocol uses a common screening platform for determining eligibility into Study 1 and Study 2. Each study has its own objectives, hypothesis testing, randomization, data collection, and adequate power for primary and secondary endpoints. Analysis and reporting are conducted separately and independently for each study.
186 studies on the registry are indexed under Axial Spondyloarthritis; 56 are open to participants now.
This study's enrollment of 734 is above the median of 108 across 122 interventional studies indexed under Axial Spondyloarthritis.
Browse Axial Spondyloarthritis studies →AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
Compared within Axial Spondyloarthritis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Spondylarthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Study 1:
Study 2:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive 15 mg upadacitinib orally once a day for 104 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment).
Drug: Upadacitinib
Participants receive matching placebo for 14 weeks and then switch to receive 15 mg upadacitinib orally once a day for 90 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment).
Drug: Upadacitinib · Drug: Placebo
Participants receive 15 mg upadacitinib orally once a day for 104 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment).
Drug: Upadacitinib
Participants receive matching placebo for 52 weeks and then switch to receive 15 mg upadacitinib orally once a day for 52 weeks. Participants who flare after 104 weeks will receive open-label upadacitinib once daily from the time of flare for 24 weeks (re-treatment).
Drug: Upadacitinib · Drug: Placebo
Upadacitinib tablet administered orally
Also known as: ABT-494, RINVOQ
Placebo for upadacitinib tablet administered orally
Study 1: Percentage of Participants Achieving Assessment of SpondyloArthritis International Society 40 (ASAS40) Response at Week 14
ASAS40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of \> 0 units) in the potential remaining domain: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Time frame: Baseline and Week 14
Study 2: Percentage of Participants Achieving an ASAS40 Response at Week 14
ASAS40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of \> 0 units) in the potential remaining domain: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Time frame: Baseline and Week 14
Study 1: Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 14
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS include Inactive disease (ASDAS \< 1.3) and very high disease (ASDAS \> 3.5). A negative change from Baseline score indicates improvement in disease activity.
Time frame: Baseline and Week 14
Study 1: Change From Baseline in Magnetic Resonance Imaging (MRI) Spondyloarthritis Research Consortium of Canada (SPARCC) Score for the Spine at Week 14
In the SPARCC MRI assessment of the spine, the entire spine was evaluated for active inflammation (bone marrow edema). Six discovertebral units (DVU) representing the 6 most abnormal DVUs were selected to calculate the MRI Spine SPARCC score. For each of the 6 DVUs, 3 consecutive sagittal slices were assessed in 4 quadrants to evaluate the extent of inflammation in all three dimensions. Each quadrant was scored for the presence (1) or absence (0) of edema. If edema was present in at least one quadrant of a DVU slice, it was also scored for intensity and depth of the edema representing that slice: An additional score of 1 was assigned if an intense signal was seen in any quadrant on a DVU slice. Slices that included a lesion demonstrating continuous increased signal of depth ≥ 1 cm extending from the endplate were scored as an additional 1 per slice. The maximum (worst) overall score for all 6 DVUs is 108. A negative change from Baseline indicates improvement.
Time frame: Baseline and Week 14
Study 1: Percentage of Participants With Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response at Week 14
The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For Questions 1 to 5 (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity. A BASDAI 50 response is defined as improvement of 50% or more from Baseline in BASDAI score.
Time frame: Baseline and Week 14
Study 1: Percentage of Participants With an ASAS20 Response at Week 14
ASAS20 response was defined as an improvement of ≥ 20% and an absolute improvement of ≥ 1 unit (on a scale of 0 to 10) from Baseline in at least 3 of the following 4 domains, with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 units \[on a scale of 0 to 10\]) in the remaining domain: * Patient's global assessment of disease activity, measured on a NRS from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the BASFI which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related BASDAI NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Time frame: Baseline and Week 14
Study 1: Percentage of Participants With ASDAS Inactive Disease at Week 14
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Inactive Disease is defined as an ASDAS score \< 1.3.
Time frame: Week 14
Study 1: Change From Baseline in Patient's Assessment of Total Back Pain at Week 14
Participants assessed their total back pain during the last week on a 0 to 10 numerical rating scale (NRS), where 0 represents no pain and 10 represents most severe pain.
Time frame: Baseline and Week 14
Study 1: Change From Baseline in Patient's Assessment of Nocturnal Back Pain at Week 14
Participants assessed the amount of back pain at night over the last week on a 0 to 10 NRS, where 0 represents no pain and 10 represents most severe pain.
Time frame: Baseline and Week 14
Study 1: Percentage of Participants With ASDAS Low Disease Activity at Week 14
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Low Disease Activity is defined as an ASDAS score \< 2.1.
Time frame: Week 14
Study 1: Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 14
The Bath Ankylosing Spondylitis Functional Index is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities such as putting on socks, bending, reaching, getting up from the floor or an armless chair, standing, climbing and other physical activities. Each item is scored on a NRS ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 to 10 with higher scores indicating more functional limitations. A negative change from Baseline in BASFI indicates improvement.
Time frame: Baseline and Week 14
Study 1: Percentage of Participants With ASAS Partial Remission at Week 14
ASAS partial remission (PR) is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Time frame: Week 14
Study 1: Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score at Week 14
The ASQoL consists of 18 items related to quality of life, including the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. Each item is answered as yes (scored as 1) or no (scored as 0). Scores are summed to obtain the overall score which ranges from 0 to 18, where higher scores indicate a worse quality of life. A negative change from Baseline in ASQoL indicates improvement in quality of life.
Time frame: Baseline and Week 14
Study 1: Change From Baseline in ASAS Health Index at Week 14
The ASAS health index (HI) measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. Each of the 17 questions is answered by the participant as "I agree" (score = 1) or "I disagree" (score = 0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, where a higher score indicates a worse health status. A negative change from Baseline indicates improvement.
Time frame: Baseline and Week 14
Study 1: Change From Baseline in Linear Bath Ankylosing Spondylitis Metrology Index (BASMI[Lin]) at Week 14
The BASMI is a composite score based on 5 direct measurements of spinal mobility: 1. cervical rotation (measured in degrees), 2. tragus to wall distance (in centimeters \[cm\]) 3. lumbar side flexion (in cm), 4. lumbar flexion (modified Schober's) (in cm) and 5. intermalleolar distance (in cm). Each measurement is converted to a linear score between 0 and 10. The total BASMI(lin) score is the average of the 5 scores and ranges from 0 to 10; the higher the BASMI(lin) score the more severe the patient's limitation of movement due to their ankylosing spondylitis. A negative change from Baseline indicates improvement.
Time frame: Baseline and Week 14
Study 1: Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 14
The MASES evaluation was conducted to assess the presence or absence of enthesitis (inflammation of the entheses, or sites where tendons or ligaments insert into the bone) at 13 different sites (first costochondral joint left/right, seventh costochondral joint left/right, posterior superior iliac spine left/right, anterior superior iliac spine left/right, iliac crest left/right, fifth lumbar spinous process, and proximal insertion of Achilles tendon left/right. Each site was scored for presence (1) or absence (0) of enthesitis. The MASES is the sum of the 13 site scores, and ranges from 0 to 13, with higher scores indicating more inflammation of the entheses. A negative change from Baseline indicates improvement.
Time frame: Baseline and Week 14
Study 1: Change From Baseline in MRI SPARCC Score for Sacroiliac Joints at Week 14
In the SPARCC MRI assessment of the sacroiliac (SI) joints 6 consecutive sacroiliac joint image coronal slices representing the largest proportion of the synovial compartment of the SI joints were assessed for edema, intensity and depth of edema. Each SI joint (left and right) was divided into quadrants for a total of 8 SI scoring locations. Each quadrant was scored for the presence (1) or absence (0) of edema, intensity of edema (a score of 1 was assigned for each SI joint (left and right) if an intense signal was seen in any quadrant of that joint for each slice), and a lesion was graded as deep (score of 1) if there was homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the articular surface of the SI joint in any quadrant. The total maximum (worst) score for all SI joints across 6 slices is 72. A negative change from Baseline indicates improvement.
Time frame: Baseline and Week 14
Study 2: Change From Baseline in ASDAS at Week 14
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS include Inactive disease (ASDAS \< 1.3) and very high disease (ASDAS \> 3.5). A negative change from Baseline score indicates improvement in disease activity.
Time frame: Baseline and Week 14
Study 2: Change From Baseline in MRI SPARCC Score for SI Joints at Week 14
In the SPARCC MRI assessment of the sacroiliac (SI) joints 6 consecutive sacroiliac joint image coronal slices representing the largest proportion of the synovial compartment of the SI joints were assessed for edema, intensity and depth of edema. Each SI joint (left and right) was divided into quadrants for a total of 8 SI scoring locations. Each quadrant was scored for the presence (1) or absence (0) of edema, intensity of edema (a score of 1 was assigned for each SI joint (left and right) if an intense signal was seen in any quadrant of that joint for each slice), and a lesion was graded as deep (score of 1) if there was homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the articular surface of the SI joint in any quadrant. The total maximum (worst) score for all SI joints across 6 slices is 72. A negative change from Baseline indicates improvement.
Time frame: Baseline and Week 14
Study 2: Percentage of Participants With BASDAI 50 Response at Week 14
The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For Questions 1 to 5 (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity. A BASDAI 50 response is defined as improvement of 50% or more from Baseline in BASDAI score.
Time frame: Baseline and Week 14
Study 2: Percentage of Participants With ASDAS Inactive Disease at Week 14
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Inactive Disease is defined as an ASDAS score \< 1.3.
Time frame: Week 14
Study 2: Change From Baseline in Patient's Assessment of Total Back Pain at Week 14
Participants assessed their total back pain during the last week on a 0 to 10 numerical rating scale (NRS), where 0 represents no pain and 10 represents most severe pain.
Time frame: Baseline and Week 14
Study 2: Change From Baseline in Patient's Assessment of Nocturnal Back Pain at Week 14
Participants assessed the amount of back pain at night over the last week on a 0 to 10 NRS, where 0 represents no pain and 10 represents most severe pain.
Time frame: Baseline and Week 14
Study 2: Percentage of Participants With ASDAS Low Disease Activity at Week 14
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Low Disease Activity is defined as an ASDAS score \< 2.1.
Time frame: Week 14
Study 2: Percentage of Participants With ASAS Partial Remission at Week 14
ASAS partial remission (PR) is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Time frame: Week 14
Study 2: Change From Baseline in BASFI at Week 14
The Bath Ankylosing Spondylitis Functional Index is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities such as putting on socks, bending, reaching, getting up from the floor or an armless chair, standing, climbing and other physical activities. Each item is scored on a NRS ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 to 10 with higher scores indicating more functional limitations. A negative change from Baseline in BASFI indicates improvement.
Time frame: Baseline and Week 14
Study 2: Change From Baseline in ASQoL at Week 14
The ASQoL consists of 18 items related to quality of life, including the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. Each item is answered as yes (scored as 1) or no (scored as 0). Scores are summed to obtain the overall score which ranges from 0 to 18, where higher scores indicate a worse quality of life. A negative change from Baseline in ASQoL indicates improvement in quality of life.
Time frame: Baseline and Week 14
Study 2: Change From Baseline in ASAS Health Index at Week 14
The ASAS HI measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. Each of the 17 questions is answered by the participant as "I agree" (score = 1) or "I disagree" (score = 0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, where a higher score indicates a worse health status. A negative change from Baseline indicates improvement.
Time frame: Baseline and Week 14
Study 2: Percentage of Participants Achieving an ASAS20 Response at Week 14
ASAS20 response was defined as an improvement of ≥ 20% and an absolute improvement of ≥ 1 unit (on a scale of 0 to 10) from Baseline in at least 3 of the following 4 domains, with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 units \[on a scale of 0 to 10\]) in the remaining domain: * Patient's global assessment of disease activity, measured on a NRS from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the BASFI which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related BASDAI NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Time frame: Baseline and Week 14
Study 2: Change From Baseline in BASMI(Lin) at Week 14
The BASMI is a composite score based on 5 direct measurements of spinal mobility: 1. cervical rotation (measured in degrees), 2. tragus to wall distance (in centimeters \[cm\]) 3. lumbar side flexion (in cm), 4. lumbar flexion (modified Schober's) (in cm) and 5. intermalleolar distance (in cm). Each measurement is converted to a linear score between 0 and 10. The total BASMI(lin) score is the average of the 5 scores and ranges from 0 to 10; the higher the BASMI(lin) score the more severe the patient's limitation of movement due to their ankylosing spondylitis. A negative change from Baseline indicates improvement.
Time frame: Baseline and Week 14
Study 2: Change From Baseline in MASES at Week 14
The MASES evaluation was conducted to assess the presence or absence of enthesitis (inflammation of the entheses, or sites where tendons or ligaments insert into the bone) at 13 different sites (first costochondral joint left/right, seventh costochondral joint left/right, posterior superior iliac spine left/right, anterior superior iliac spine left/right, iliac crest left/right, fifth lumbar spinous process, and proximal insertion of Achilles tendon left/right. Each site was scored for presence (1) or absence (0) of enthesitis. The MASES is the sum of the 13 site scores, and ranges from 0 to 13, with higher scores indicating more inflammation of the entheses. A negative change from Baseline indicates improvement.
Time frame: Baseline and Week 14
Study 2: Percentage of Participants Achieving an ASAS40 Response at Week 52
ASAS40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of \> 0 units) in the potential remaining domain: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
Time frame: Baseline and Week 52
Study 2: Change From Baseline in MRI SPARCC Score for the Spine at Week 14
In the SPARCC MRI assessment of the spine, the entire spine is evaluated for active inflammation (bone marrow edema). Six discovertebral units (DVU) representing the 6 most abnormal DVUs were selected to calculate the MRI Spine SPARCC score. For each of the 6 DVUs, 3 consecutive sagittal slices were assessed in 4 quadrants to evaluate the extent of inflammation in all three dimensions. Each quadrant was scored for the presence (1) or absence (0) of edema. If edema was present in at least one quadrant of a DVU slice, it was also scored for intensity and depth of the edema representing that slice: An additional score of 1 was assigned if an intense signal was seen in any quadrant on a DVU slice. Slices that included a lesion demonstrating continuous increased signal of depth ≥ 1 cm extending from the endplate were scored as an additional 1 per slice. The maximum (worst) overall score for all 6 DVUs is 108. A negative change from Baseline indicates improvement.
Time frame: Baseline and Week 14
Study 2: Percentage of Participants Who Initiated Rescue Treatment Between Week 24 and Week 52
Participants who did not achieve an ASAS20 response at any 2 consecutive scheduled visits from Week 24 through Week 52 were to be rescued with standard of care treatment as described in the protocol.
Time frame: Week 24, Week 32, Week 40, and Week 52
Study 2: Percentage of Participants With ASDAS Major Improvement at Week 52
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS include Inactive disease (ASDAS \< 1.3) and very high disease (ASDAS \> 3.5). Major Improvement is defined as a change from Baseline of ≤ -2.0.
Time frame: Baseline and Week 52
Study 2: Percentage of Participants With ASDAS Inactive Disease at Week 52
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Inactive Disease is defined as an ASDAS score \< 1.3.
Time frame: Week 52
Study 2: Percentage of Participants With ASDAS Low Disease Activity at Week 52
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Low Disease Activity is defined as an ASDAS score \< 2.1.
Time frame: Week 52
This master protocol consists of 2 independent studies with a common screening platform for adults with active axial spondyloarthritis (axSpA). Study 1 enrolled adults with ankylosing spondylitis (AS) who had an inadequate response (IR) to biologic disease-modifying antirheumatic drug (bDMARD) therapy. Study 2 enrolled adults with non-radiographic axSpA (nr-axSpA). Each study includes a double-blind treatment period and an ongoing open-label extension period. RW period entry was optional.
| Milestone | DB Study 1: Placebo | DB Study 1: Upadacitinib 15 mg | DB Study 2: Placebo | DB Study 2: Upadacitinib 15 mg | OL Study 1: Upadacitinib 15 mg | OL Study 2: Upadacitinib 15 mg | RW Study 1: Off Upadacitinib - No Flare | RW Study 2: Off Upadacitinib - No Flare | RW Study 1: Upadacitinib 15 mg - No Flare | RW Study 2: Upadacitinib 15 mg - No Flare | RW Study 1: Upadacitinib 15 mg - Flare | RW Study 2: Upadacitinib 15 mg - Flare | RW Study 1: Upadacitinib 15 mg - Extension | RW Study 2: Upadacitinib 15 mg - Extension |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 209 | 211 | 158 | 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received study drug | 209 | 211 | 157 | 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 204 | 206 | 138 | 133 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 5 | 5 | 20 | 23 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 0 | 12 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Covid-19 logistical restrictions | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 1 | 3 | 7 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | DB Study 1: Placebo | DB Study 1: Upadacitinib 15 mg | DB Study 2: Placebo | DB Study 2: Upadacitinib 15 mg | OL Study 1: Upadacitinib 15 mg | OL Study 2: Upadacitinib 15 mg | RW Study 1: Off Upadacitinib - No Flare | RW Study 2: Off Upadacitinib - No Flare | RW Study 1: Upadacitinib 15 mg - No Flare | RW Study 2: Upadacitinib 15 mg - No Flare | RW Study 1: Upadacitinib 15 mg - Flare | RW Study 2: Upadacitinib 15 mg - Flare | RW Study 1: Upadacitinib 15 mg - Extension | RW Study 2: Upadacitinib 15 mg - Extension |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 410 | 271 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 349 | 239 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 61 | 32 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 5 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 23 | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 7 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Covid-19 infection | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Covid-19 logistical restrictions | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 20 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Geo-political restrictions | 0 | 0 | 0 | 0 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Missing | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | DB Study 1: Placebo | DB Study 1: Upadacitinib 15 mg | DB Study 2: Placebo | DB Study 2: Upadacitinib 15 mg | OL Study 1: Upadacitinib 15 mg | OL Study 2: Upadacitinib 15 mg | RW Study 1: Off Upadacitinib - No Flare | RW Study 2: Off Upadacitinib - No Flare | RW Study 1: Upadacitinib 15 mg - No Flare | RW Study 2: Upadacitinib 15 mg - No Flare | RW Study 1: Upadacitinib 15 mg - Flare | RW Study 2: Upadacitinib 15 mg - Flare | RW Study 1: Upadacitinib 15 mg - Extension | RW Study 2: Upadacitinib 15 mg - Extension |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 18 | 23 | 3 | 5 | 93 | 52 | 66 | 61 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 19 | 3 | 5 | 91 | 50 | 64 | 58 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 0 | 0 | 2 | 2 | 2 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
ASAS40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of \> 0 units) in the potential remaining domain: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
| percentage of participants | Study 1: Placebo | Study 1: Upadacitinib 15 mg |
|---|---|---|
| Study 1: Percentage of Participants Achieving Assessment of SpondyloArthritis International Society 40 (ASAS40) Response at Week 14 | 18.2 (13.0 to 23.4) | 44.5 (37.8 to 51.3) |
ASAS40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of \> 0 units) in the potential remaining domain: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
| percentage of participants | Study 2: Placebo | Study 2: Upadacitinib 15 mg |
|---|---|---|
| Study 2: Percentage of Participants Achieving an ASAS40 Response at Week 14 | 22.5 (16.0 to 29.1) | 44.9 (37.1 to 52.7) |
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS include Inactive disease (ASDAS \< 1.3) and very high disease (ASDAS \> 3.5). A negative change from Baseline score indicates improvement in disease activity.
| score on a scale | Study 1: Placebo | Study 1: Upadacitinib 15 mg |
|---|---|---|
| Study 1: Change From Baseline in Ankylosing Spondylitis Disease Activity Score (ASDAS) at Week 14 | -0.49 (-0.62 to -0.37) | -1.52 (-1.64 to -1.39) |
In the SPARCC MRI assessment of the spine, the entire spine was evaluated for active inflammation (bone marrow edema). Six discovertebral units (DVU) representing the 6 most abnormal DVUs were selected to calculate the MRI Spine SPARCC score. For each of the 6 DVUs, 3 consecutive sagittal slices were assessed in 4 quadrants to evaluate the extent of inflammation in all three dimensions. Each quadrant was scored for the presence (1) or absence (0) of edema. If edema was present in at least one quadrant of a DVU slice, it was also scored for intensity and depth of the edema representing that slice: An additional score of 1 was assigned if an intense signal was seen in any quadrant on a DVU slice. Slices that included a lesion demonstrating continuous increased signal of depth ≥ 1 cm extending from the endplate were scored as an additional 1 per slice. The maximum (worst) overall score for all 6 DVUs is 108. A negative change from Baseline indicates improvement.
| score on a scale | Study 1: Placebo | Study 1: Upadacitinib 15 mg |
|---|---|---|
| Study 1: Change From Baseline in Magnetic Resonance Imaging (MRI) Spondyloarthritis Research Consortium of Canada (SPARCC) Score for the Spine at Week 14 | -0.04 (-1.14 to 1.06) | -3.95 (-5.06 to -2.83) |
The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For Questions 1 to 5 (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity. A BASDAI 50 response is defined as improvement of 50% or more from Baseline in BASDAI score.
| percentage of participants | Study 1: Placebo | Study 1: Upadacitinib 15 mg |
|---|---|---|
| Study 1: Percentage of Participants With Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Response at Week 14 | 16.7 (11.7 to 21.8) | 43.1 (36.4 to 49.8) |
ASAS20 response was defined as an improvement of ≥ 20% and an absolute improvement of ≥ 1 unit (on a scale of 0 to 10) from Baseline in at least 3 of the following 4 domains, with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 units \[on a scale of 0 to 10\]) in the remaining domain: * Patient's global assessment of disease activity, measured on a NRS from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the BASFI which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related BASDAI NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
| percentage of participants | Study 1: Placebo | Study 1: Upadacitinib 15 mg |
|---|---|---|
| Study 1: Percentage of Participants With an ASAS20 Response at Week 14 | 38.3 (31.7 to 44.9) | 65.4 (59.0 to 71.8) |
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Inactive Disease is defined as an ASDAS score \< 1.3.
| percentage of participants | Study 1: Placebo | Study 1: Upadacitinib 15 mg |
|---|---|---|
| Study 1: Percentage of Participants With ASDAS Inactive Disease at Week 14 | 1.9 (0.1 to 3.8) | 12.8 (8.3 to 17.3) |
Participants assessed their total back pain during the last week on a 0 to 10 numerical rating scale (NRS), where 0 represents no pain and 10 represents most severe pain.
| score on a scale | Study 1: Placebo | Study 1: Upadacitinib 15 mg |
|---|---|---|
| Study 1: Change From Baseline in Patient's Assessment of Total Back Pain at Week 14 | -1.47 (-1.77 to -1.16) | -3.00 (-3.30 to -2.70) |
Participants assessed the amount of back pain at night over the last week on a 0 to 10 NRS, where 0 represents no pain and 10 represents most severe pain.
| score on a scale | Study 1: Placebo | Study 1: Upadacitinib 15 mg |
|---|---|---|
| Study 1: Change From Baseline in Patient's Assessment of Nocturnal Back Pain at Week 14 | -1.52 (-1.84 to -1.20) | -3.21 (-3.52 to -2.89) |
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Low Disease Activity is defined as an ASDAS score \< 2.1.
| percentage of participants | Study 1: Placebo | Study 1: Upadacitinib 15 mg |
|---|---|---|
| Study 1: Percentage of Participants With ASDAS Low Disease Activity at Week 14 | 10.1 (6.0 to 14.2) | 44.1 (37.4 to 50.8) |
The Bath Ankylosing Spondylitis Functional Index is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities such as putting on socks, bending, reaching, getting up from the floor or an armless chair, standing, climbing and other physical activities. Each item is scored on a NRS ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 to 10 with higher scores indicating more functional limitations. A negative change from Baseline in BASFI indicates improvement.
| score on a scale | Study 1: Placebo | Study 1: Upadacitinib 15 mg |
|---|---|---|
| Study 1: Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 14 | -1.09 (-1.35 to -0.83) | -2.26 (-2.53 to -2.00) |
ASAS partial remission (PR) is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
| percentage of participants | Study 1: Placebo | Study 1: Upadacitinib 15 mg |
|---|---|---|
| Study 1: Percentage of Participants With ASAS Partial Remission at Week 14 | 4.3 (1.6 to 7.1) | 17.5 (12.4 to 22.7) |
The ASQoL consists of 18 items related to quality of life, including the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. Each item is answered as yes (scored as 1) or no (scored as 0). Scores are summed to obtain the overall score which ranges from 0 to 18, where higher scores indicate a worse quality of life. A negative change from Baseline in ASQoL indicates improvement in quality of life.
| score on a scale | Study 1: Placebo | Study 1: Upadacitinib 15 mg |
|---|---|---|
| Study 1: Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score at Week 14 | -2.03 (-2.62 to -1.44) | -5.10 (-5.69 to -4.52) |
The ASAS health index (HI) measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. Each of the 17 questions is answered by the participant as "I agree" (score = 1) or "I disagree" (score = 0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, where a higher score indicates a worse health status. A negative change from Baseline indicates improvement.
| score on a scale | Study 1: Placebo | Study 1: Upadacitinib 15 mg |
|---|---|---|
| Study 1: Change From Baseline in ASAS Health Index at Week 14 | -1.07 (-1.51 to -0.64) | -2.93 (-3.36 to -2.50) |
The BASMI is a composite score based on 5 direct measurements of spinal mobility: 1. cervical rotation (measured in degrees), 2. tragus to wall distance (in centimeters \[cm\]) 3. lumbar side flexion (in cm), 4. lumbar flexion (modified Schober's) (in cm) and 5. intermalleolar distance (in cm). Each measurement is converted to a linear score between 0 and 10. The total BASMI(lin) score is the average of the 5 scores and ranges from 0 to 10; the higher the BASMI(lin) score the more severe the patient's limitation of movement due to their ankylosing spondylitis. A negative change from Baseline indicates improvement.
| score on a scale | Study 1: Placebo | Study 1: Upadacitinib 15 mg |
|---|---|---|
| Study 1: Change From Baseline in Linear Bath Ankylosing Spondylitis Metrology Index (BASMI[Lin]) at Week 14 | -0.16 (-0.26 to -0.06) | -0.48 (-0.58 to -0.38) |
The MASES evaluation was conducted to assess the presence or absence of enthesitis (inflammation of the entheses, or sites where tendons or ligaments insert into the bone) at 13 different sites (first costochondral joint left/right, seventh costochondral joint left/right, posterior superior iliac spine left/right, anterior superior iliac spine left/right, iliac crest left/right, fifth lumbar spinous process, and proximal insertion of Achilles tendon left/right. Each site was scored for presence (1) or absence (0) of enthesitis. The MASES is the sum of the 13 site scores, and ranges from 0 to 13, with higher scores indicating more inflammation of the entheses. A negative change from Baseline indicates improvement.
| score on a scale | Study 1: Placebo | Study 1: Upadacitinib 15 mg |
|---|---|---|
| Study 1: Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 14 | -1.1 (-1.5 to -0.8) | -2.6 (-3.0 to -2.2) |
In the SPARCC MRI assessment of the sacroiliac (SI) joints 6 consecutive sacroiliac joint image coronal slices representing the largest proportion of the synovial compartment of the SI joints were assessed for edema, intensity and depth of edema. Each SI joint (left and right) was divided into quadrants for a total of 8 SI scoring locations. Each quadrant was scored for the presence (1) or absence (0) of edema, intensity of edema (a score of 1 was assigned for each SI joint (left and right) if an intense signal was seen in any quadrant of that joint for each slice), and a lesion was graded as deep (score of 1) if there was homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the articular surface of the SI joint in any quadrant. The total maximum (worst) score for all SI joints across 6 slices is 72. A negative change from Baseline indicates improvement.
| score on a scale | Study 1: Placebo | Study 1: Upadacitinib 15 mg |
|---|---|---|
| Study 1: Change From Baseline in MRI SPARCC Score for Sacroiliac Joints at Week 14 | 1.05 (0.22 to 1.89) | -2.26 (-3.10 to -1.41) |
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS include Inactive disease (ASDAS \< 1.3) and very high disease (ASDAS \> 3.5). A negative change from Baseline score indicates improvement in disease activity.
| score on a scale | Study 2: Placebo | Study 2: Upadacitinib 15 mg |
|---|---|---|
| Study 2: Change From Baseline in ASDAS at Week 14 | -0.71 (-0.85 to -0.56) | -1.36 (-1.50 to -1.21) |
In the SPARCC MRI assessment of the sacroiliac (SI) joints 6 consecutive sacroiliac joint image coronal slices representing the largest proportion of the synovial compartment of the SI joints were assessed for edema, intensity and depth of edema. Each SI joint (left and right) was divided into quadrants for a total of 8 SI scoring locations. Each quadrant was scored for the presence (1) or absence (0) of edema, intensity of edema (a score of 1 was assigned for each SI joint (left and right) if an intense signal was seen in any quadrant of that joint for each slice), and a lesion was graded as deep (score of 1) if there was homogeneous and unequivocal increase in signal extending over a depth of at least 1 cm from the articular surface of the SI joint in any quadrant. The total maximum (worst) score for all SI joints across 6 slices is 72. A negative change from Baseline indicates improvement.
| score on a scale | Study 2: Placebo | Study 2: Upadacitinib 15 mg |
|---|---|---|
| Study 2: Change From Baseline in MRI SPARCC Score for SI Joints at Week 14 | 0.57 (-0.17 to 1.30) | -2.49 (-3.22 to -1.77) |
The BASDAI assesses disease activity by asking the participant to answer 6 questions (each on an 11 point numeric rating scale \[NRS\]) pertaining to symptoms experienced for the past week. For Questions 1 to 5 (level of fatigue/tiredness, level of AS neck, back or hip pain, level of pain/swelling in joints, other than neck, back or hips, level of discomfort from any areas tender to touch or pressure, and level of morning stiffness), the response is from 0 (none) to 10 (very severe); for Question 6 (duration of morning stiffness), the response is from 0 (0 hours) to 10 (≥ 2 hours). The overall BASDAI score ranges from 0 to 10. Lower scores indicate less disease activity. A BASDAI 50 response is defined as improvement of 50% or more from Baseline in BASDAI score.
| percentage of participants | Study 2: Placebo | Study 2: Upadacitinib 15 mg |
|---|---|---|
| Study 2: Percentage of Participants With BASDAI 50 Response at Week 14 | 22.1 (15.5 to 28.6) | 42.3 (34.6 to 50.1) |
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Inactive Disease is defined as an ASDAS score \< 1.3.
| percentage of participants | Study 2: Placebo | Study 2: Upadacitinib 15 mg |
|---|---|---|
| Study 2: Percentage of Participants With ASDAS Inactive Disease at Week 14 | 5.2 (1.7 to 8.7) | 14.1 (8.6 to 19.6) |
Participants assessed their total back pain during the last week on a 0 to 10 numerical rating scale (NRS), where 0 represents no pain and 10 represents most severe pain.
| score on a scale | Study 2: Placebo | Study 2: Upadacitinib 15 mg |
|---|---|---|
| Study 2: Change From Baseline in Patient's Assessment of Total Back Pain at Week 14 | -2.00 (-2.35 to -1.65) | -2.91 (-3.27 to -2.56) |
Participants assessed the amount of back pain at night over the last week on a 0 to 10 NRS, where 0 represents no pain and 10 represents most severe pain.
| score on a scale | Study 2: Placebo | Study 2: Upadacitinib 15 mg |
|---|---|---|
| Study 2: Change From Baseline in Patient's Assessment of Nocturnal Back Pain at Week 14 | -1.84 (-2.23 to -1.44) | -2.96 (-3.36 to -2.56) |
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Low Disease Activity is defined as an ASDAS score \< 2.1.
| percentage of participants | Study 2: Placebo | Study 2: Upadacitinib 15 mg |
|---|---|---|
| Study 2: Percentage of Participants With ASDAS Low Disease Activity at Week 14 | 18.3 (12.2 to 24.4) | 42.3 (34.6 to 50.1) |
ASAS partial remission (PR) is defined as an absolute score of ≤ 2 units on a 0 to 10 scale for each of the four following domains: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
| percentage of participants | Study 2: Placebo | Study 2: Upadacitinib 15 mg |
|---|---|---|
| Study 2: Percentage of Participants With ASAS Partial Remission at Week 14 | 7.6 (3.5 to 11.8) | 18.6 (12.5 to 24.7) |
The Bath Ankylosing Spondylitis Functional Index is a validated index to determine the degree of functional limitation in patients with AS. BASFI consists of 10 questions assessing participants' ability to perform activities such as putting on socks, bending, reaching, getting up from the floor or an armless chair, standing, climbing and other physical activities. Each item is scored on a NRS ranging from 0 (easy to perform an activity) to 10 (impossible to perform an activity). The overall score is the mean of the 10 items and ranges from 0 to 10 with higher scores indicating more functional limitations. A negative change from Baseline in BASFI indicates improvement.
| score on a scale | Study 2: Placebo | Study 2: Upadacitinib 15 mg |
|---|---|---|
| Study 2: Change From Baseline in BASFI at Week 14 | -1.47 (-1.79 to -1.15) | -2.61 (-2.94 to -2.29) |
The ASQoL consists of 18 items related to quality of life, including the impact of pain on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. Each item is answered as yes (scored as 1) or no (scored as 0). Scores are summed to obtain the overall score which ranges from 0 to 18, where higher scores indicate a worse quality of life. A negative change from Baseline in ASQoL indicates improvement in quality of life.
| score on a scale | Study 2: Placebo | Study 2: Upadacitinib 15 mg |
|---|---|---|
| Study 2: Change From Baseline in ASQoL at Week 14 | -3.15 (-3.87 to -2.43) | -5.38 (-6.11 to -4.65) |
The ASAS HI measures functioning and health across 17 aspects of health in patients with AS, including pain, emotional functions, sleep, sexual function, mobility, self care, and community life. Each of the 17 questions is answered by the participant as "I agree" (score = 1) or "I disagree" (score = 0). The responses to the 17 dichotomous items are summed up to give a total score ranging from 0 to 17, where a higher score indicates a worse health status. A negative change from Baseline indicates improvement.
| score on a scale | Study 2: Placebo | Study 2: Upadacitinib 15 mg |
|---|---|---|
| Study 2: Change From Baseline in ASAS Health Index at Week 14 | -1.48 (-2.02 to -0.93) | -3.26 (-3.81 to -2.70) |
ASAS20 response was defined as an improvement of ≥ 20% and an absolute improvement of ≥ 1 unit (on a scale of 0 to 10) from Baseline in at least 3 of the following 4 domains, with no deterioration (defined as a worsening of ≥ 20% and a net worsening of ≥ 1 units \[on a scale of 0 to 10\]) in the remaining domain: * Patient's global assessment of disease activity, measured on a NRS from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the BASFI which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related BASDAI NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
| percentage of participants | Study 2: Placebo | Study 2: Upadacitinib 15 mg |
|---|---|---|
| Study 2: Percentage of Participants Achieving an ASAS20 Response at Week 14 | 43.8 (36.0 to 51.5) | 66.7 (59.3 to 74.1) |
The BASMI is a composite score based on 5 direct measurements of spinal mobility: 1. cervical rotation (measured in degrees), 2. tragus to wall distance (in centimeters \[cm\]) 3. lumbar side flexion (in cm), 4. lumbar flexion (modified Schober's) (in cm) and 5. intermalleolar distance (in cm). Each measurement is converted to a linear score between 0 and 10. The total BASMI(lin) score is the average of the 5 scores and ranges from 0 to 10; the higher the BASMI(lin) score the more severe the patient's limitation of movement due to their ankylosing spondylitis. A negative change from Baseline indicates improvement.
| score on a scale | Study 2: Placebo | Study 2: Upadacitinib 15 mg |
|---|---|---|
| Study 2: Change From Baseline in BASMI(Lin) at Week 14 | -0.19 (-0.29 to -0.08) | -0.29 (-0.40 to -0.18) |
The MASES evaluation was conducted to assess the presence or absence of enthesitis (inflammation of the entheses, or sites where tendons or ligaments insert into the bone) at 13 different sites (first costochondral joint left/right, seventh costochondral joint left/right, posterior superior iliac spine left/right, anterior superior iliac spine left/right, iliac crest left/right, fifth lumbar spinous process, and proximal insertion of Achilles tendon left/right. Each site was scored for presence (1) or absence (0) of enthesitis. The MASES is the sum of the 13 site scores, and ranges from 0 to 13, with higher scores indicating more inflammation of the entheses. A negative change from Baseline indicates improvement.
| score on a scale | Study 2: Placebo | Study 2: Upadacitinib 15 mg |
|---|---|---|
| Study 2: Change From Baseline in MASES at Week 14 | -1.6 (-2.0 to -1.2) | -2.3 (-2.7 to -1.9) |
ASAS40 response was defined as improvement of ≥ 40% relative to Baseline and absolute improvement of ≥ 2 units (on a scale from 0 to 10) in ≥ 3 of the following 4 domains with no deterioration (defined as a net worsening of \> 0 units) in the potential remaining domain: * Patient's global assessment of disease activity, measured on a numeric rating scale (NRS) from 0 (no activity) to 10 (severe activity); * Pain, measured by the total back pain NRS from 0 (no pain) to 10 (most severe pain); * Function, measured by the Bath Ankylosing Spondylitis Functional Index (BASFI) which consists of 10 items assessing participants' ability to perform activities on an NRS ranging from 0 (easy) to 10 (impossible); * Inflammation, measured by the mean of the 2 morning stiffness-related Bath AS Disease Activity Index (BASDAI) NRS scores (items 5 \[level of stiffness\] and 6 \[duration of stiffness\]) each on a scale from 0 (none/0 hours) to 10 (very severe/2 hours or more duration).
| percentage of participants | Study 2: Placebo | Study 2: Upadacitinib 15 mg |
|---|---|---|
| Study 2: Percentage of Participants Achieving an ASAS40 Response at Week 52 | 42.7 (34.9 to 50.4) | 62.8 (55.2 to 70.4) |
In the SPARCC MRI assessment of the spine, the entire spine is evaluated for active inflammation (bone marrow edema). Six discovertebral units (DVU) representing the 6 most abnormal DVUs were selected to calculate the MRI Spine SPARCC score. For each of the 6 DVUs, 3 consecutive sagittal slices were assessed in 4 quadrants to evaluate the extent of inflammation in all three dimensions. Each quadrant was scored for the presence (1) or absence (0) of edema. If edema was present in at least one quadrant of a DVU slice, it was also scored for intensity and depth of the edema representing that slice: An additional score of 1 was assigned if an intense signal was seen in any quadrant on a DVU slice. Slices that included a lesion demonstrating continuous increased signal of depth ≥ 1 cm extending from the endplate were scored as an additional 1 per slice. The maximum (worst) overall score for all 6 DVUs is 108. A negative change from Baseline indicates improvement.
| score on a scale | Study 2: Placebo | Study 2: Upadacitinib 15 mg |
|---|---|---|
| Study 2: Change From Baseline in MRI SPARCC Score for the Spine at Week 14 | 0.34 (-0.32 to 1.00) | -0.79 (-1.48 to -0.11) |
Participants who did not achieve an ASAS20 response at any 2 consecutive scheduled visits from Week 24 through Week 52 were to be rescued with standard of care treatment as described in the protocol.
| percentage of participants | Study 2: Placebo | Study 2: Upadacitinib 15 mg |
|---|---|---|
| Week 24 | 13.4 (8.5 to 19.7) | 5.1 (2.2 to 9.9) |
| Week 32 | 1.9 (0.4 to 5.5) | 3.2 (1.0 to 7.3) |
| Week 40 | 0.6 (0.0 to 3.5) | 0.6 (0.0 to 3.5) |
| Week 52 | 1.3 (0.2 to 4.5) | 0 (0.0 to 2.3) |
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score; published ranges for disease activity states as defined by the ASDAS include Inactive disease (ASDAS \< 1.3) and very high disease (ASDAS \> 3.5). Major Improvement is defined as a change from Baseline of ≤ -2.0.
| percentage of participants | Study 2: Placebo | Study 2: Upadacitinib 15 mg |
|---|---|---|
| Study 2: Percentage of Participants With ASDAS Major Improvement at Week 52 | 20.4 (14.1 to 26.7) | 37.8 (30.2 to 45.4) |
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Inactive Disease is defined as an ASDAS score \< 1.3.
| percentage of participants | Study 2: Placebo | Study 2: Upadacitinib 15 mg |
|---|---|---|
| Study 2: Percentage of Participants With ASDAS Inactive Disease at Week 52 | 10.8 (6.0 to 15.7) | 32.7 (25.3 to 40.1) |
ASDAS is a composite index to assess disease activity in Ankylosing Spondylitis. ASDAS combines the following 5 disease activity variables using a weighted formula: 1. Patient's assessment of total back pain (BASDAI Question 2; NRS score 0 \[none\] - 10 \[very severe\]) 2. Patient global assessment of disease activity (NRS score 0 \[no activity\] - 10 \[severe activity\]) 3. Peripheral pain/swelling (BASDAI Question 3; NRS score 0 \[none\] - 10 \[very severe\]) 4. Duration of morning stiffness (BASDAI Question 6; NRS score 0 \[0 hours\] - 10 \[2 or more hours\]) 5. High-sensitivity C-reactive protein (hs-CRP) in mg/L. The overall score ranges from 0 with no defined upper score. ASDAS Low Disease Activity is defined as an ASDAS score \< 2.1.
| percentage of participants | Study 2: Placebo | Study 2: Upadacitinib 15 mg |
|---|---|---|
| Study 2: Percentage of Participants With ASDAS Low Disease Activity at Week 52 | 32.5 (25.2 to 39.9) | 55.8 (48.0 to 63.6) |
Collected over All-cause mortality and adverse event tables include events reported from the start of safety data collection/time of informed consent/enrollment (all are acceptable; whichever study team prefers per protocol/study design) to the end of the study. The median time on follow-up (or mean time participants were followed) was 769.5, 902.5, 837.0, 861.0, 794.0, 1015.0, 0.0, 1183.0, 1026.0, 1059.0, 1092.0, 1081.0, 1226.5, and 1182.0 days for arms:. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB Study 1: Placebo | 0/209 (0%) | 1/209 (0.5%) | 35/209 (16.7%) |
| DB Study 1: Upadacitinib 15 mg | 0/211 (0%) | 6/211 (2.8%) | 41/211 (19.4%) |
| OL Study 1: Upadacitinib 15 mg | 1/410 (0.2%) | 44/410 (10.7%) | 172/410 (42%) |
| DB Study 2: Placebo | 0/158 (0%) | 6/158 (3.8%) | 69/158 (43.7%) |
| DB Study 2: Upadacitinib 15 mg | 0/156 (0%) | 7/156 (4.5%) | 67/156 (42.9%) |
| OL Study 2: Upadacitinib 15 mg | 0/271 (0%) | 22/271 (8.1%) | 107/271 (39.5%) |
| RW Study 1: Upadacitinib 15 mg - No Flare | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| RW Study 2: Upadacitinib 15 mg - No Flare | 0/5 (0%) | 1/5 (20%) | 4/5 (80%) |
| RW Study 1: Upadacitinib 15 mg - Flare | 0/93 (0%) | 2/93 (2.2%) | 28/93 (30.1%) |
| RW Study 2: Upadacitinib 15 mg - Flare | 0/52 (0%) | 3/52 (5.8%) | 19/52 (36.5%) |
| RW Study 1: Off Upadacitinib - No Flare | 0/18 (0%) | 0/18 (0%) | 4/18 (22.2%) |
| RW Study 2: Off Upadacitinib - No Flare | 0/23 (0%) | 2/23 (8.7%) | 6/23 (26.1%) |
| RW Study 1: Upadacitinib 15 mg - Extension | 0/66 (0%) | 2/66 (3%) | 20/66 (30.3%) |
| RW Study 2: Upadacitinib 15 mg - Extension | 0/61 (0%) | 2/61 (3.3%) | 22/61 (36.1%) |
| Event | DB Study 1: Placebo | DB Study 1: Upadacitinib 15 mg | OL Study 1: Upadacitinib 15 mg | DB Study 2: Placebo | DB Study 2: Upadacitinib 15 mg | OL Study 2: Upadacitinib 15 mg | RW Study 1: Upadacitinib 15 mg - No Flare | RW Study 2: Upadacitinib 15 mg - No Flare | RW Study 1: Upadacitinib 15 mg - Flare | RW Study 2: Upadacitinib 15 mg - Flare | RW Study 1: Off Upadacitinib - No Flare | RW Study 2: Off Upadacitinib - No Flare | RW Study 1: Upadacitinib 15 mg - Extension | RW Study 2: Upadacitinib 15 mg - Extension |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HYPERTENSIONVascular disorders | 0/209 | 0/211 | 0/410 | 0/158 | 0/156 | 1/271 | 0/3 | 1/5 | 0/93 | 0/52 | 0/18 | 0/23 | 0/66 | 0/61 |
| PNEUMONIA VIRALInfections and infestations | 0/209 | 0/211 | 0/410 | 0/158 | 0/156 | 0/271 | 0/3 | 0/5 | 0/93 | 0/52 | 0/18 | 1/23 | 0/66 | 0/61 |
| SEIZURENervous system disorders | 0/209 | 0/211 | 0/410 | 0/158 | 0/156 | 0/271 | 0/3 | 0/5 | 0/93 | 0/52 | 0/18 | 1/23 | 0/66 | 0/61 |
| LATENT SYPHILISInfections and infestations | 0/209 | 0/211 | 0/410 | 0/158 | 0/156 | 0/271 | 0/3 | 0/5 | 0/93 | 1/52 | 0/18 | 0/23 | 0/66 | 0/61 |
| INTERVERTEBRAL DISC PROTRUSIONMusculoskeletal and connective tissue disorders | 0/209 | 0/211 | 0/410 | 0/158 | 0/156 | 0/271 | 0/3 | 0/5 | 0/93 | 1/52 | 0/18 | 0/23 | 0/66 | 0/61 |
| CERVICAL DYSPLASIAReproductive system and breast disorders | 0/209 | 0/211 | 0/410 | 0/158 | 0/156 | 0/271 | 0/3 | 0/5 | 0/93 | 1/52 | 0/18 | 0/23 | 0/66 | 0/61 |
| HEAVY MENSTRUAL BLEEDINGReproductive system and breast disorders | 0/209 | 0/211 | 0/410 | 0/158 | 0/156 | 1/271 | 0/3 | 0/5 | 0/93 | 1/52 | 0/18 | 0/23 | 0/66 | 0/61 |
| COVID-19 PNEUMONIAInfections and infestations | 0/209 | 4/211 | 7/410 | 0/158 | 1/156 | 2/271 | 0/3 | 0/5 | 0/93 | 0/52 | 0/18 | 0/23 | 0/66 | 0/61 |
| PNEUMONIAInfections and infestations | 0/209 | 0/211 | 1/410 | 0/158 | 0/156 | 0/271 | 0/3 | 0/5 | 0/93 | 0/52 | 0/18 | 0/23 | 0/66 | 1/61 |
| UTERINE LEIOMYOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/209 | 0/211 | 1/410 | 0/158 | 0/156 | 0/271 | 0/3 | 0/5 | 1/93 | 0/52 | 0/18 | 0/23 | 0/66 | 1/61 |
| Event | DB Study 1: Placebo | DB Study 1: Upadacitinib 15 mg | OL Study 1: Upadacitinib 15 mg | DB Study 2: Placebo | DB Study 2: Upadacitinib 15 mg | OL Study 2: Upadacitinib 15 mg | RW Study 1: Upadacitinib 15 mg - No Flare | RW Study 2: Upadacitinib 15 mg - No Flare | RW Study 1: Upadacitinib 15 mg - Flare | RW Study 2: Upadacitinib 15 mg - Flare | RW Study 1: Off Upadacitinib - No Flare | RW Study 2: Off Upadacitinib - No Flare | RW Study 1: Upadacitinib 15 mg - Extension | RW Study 2: Upadacitinib 15 mg - Extension |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 5/209 | 10/211 | 78/410 | 22/158 | 20/156 | 59/271 | 0/3 | 2/5 | 5/93 | 4/52 | 0/18 | 1/23 | 6/66 | 3/61 |
| ILEAL ULCERGastrointestinal disorders | 0/209 | 0/211 | 0/410 | 0/158 | 0/156 | 0/271 | 1/3 | 0/5 | 0/93 | 0/52 | 0/18 | 0/23 | 1/66 | 0/61 |
| NASOPHARYNGITISInfections and infestations | 3/209 | 5/211 | 28/410 | 8/158 | 12/156 | 16/271 | 1/3 | 1/5 | 8/93 | 4/52 | 0/18 | 2/23 | 4/66 | 2/61 |
| LIMB INJURYInjury, poisoning and procedural complications | 0/209 | 0/211 | 1/410 | 0/158 | 1/156 | 0/271 | 1/3 | 0/5 | 0/93 | 0/52 | 0/18 | 0/23 | 0/66 | 0/61 |
| PLATELET COUNT DECREASEDInvestigations | 0/209 | 0/211 | 0/410 | 0/158 | 0/156 | 0/271 | 1/3 | 0/5 | 0/93 | 0/52 | 0/18 | 0/23 | 0/66 | 0/61 |
| WEIGHT INCREASEDInvestigations | 0/209 | 1/211 | 1/410 | 0/158 | 5/156 | 4/271 | 1/3 | 0/5 | 0/93 | 0/52 | 0/18 | 0/23 | 0/66 | 0/61 |
| ECZEMASkin and subcutaneous tissue disorders | 0/209 | 0/211 | 0/410 | 2/158 | 0/156 | 1/271 | 1/3 | 0/5 | 0/93 | 0/52 | 0/18 | 0/23 | 0/66 | 1/61 |
| ARTERIOSCLEROSIS CORONARY ARTERYCardiac disorders | 0/209 | 0/211 | 0/410 | 0/158 | 0/156 | 0/271 | 0/3 | 1/5 | 0/93 | 0/52 | 0/18 | 0/23 | 0/66 | 0/61 |
| CHEST DISCOMFORTGeneral disorders | 0/209 | 0/211 | 1/410 | 0/158 | 0/156 | 0/271 | 0/3 | 1/5 | 0/93 | 0/52 | 0/18 | 0/23 | 0/66 | 0/61 |
| POST-ACUTE COVID-19 SYNDROMEInfections and infestations | 0/209 | 0/211 | 1/410 | 0/158 | 2/156 | 0/271 | 0/3 | 1/5 | 0/93 | 0/52 | 0/18 | 0/23 | 0/66 | 0/61 |
The full analysis set (FAS) includes all randomized participants who received at least one dose of study drug (upadacitinib or placebo).
| Age, Continuous(years) | Study 1: Placebo | Study 1: Upadacitinib 15 mg | Study 2: Placebo | Study 2: Upadacitinib 15 mg | Total |
|---|---|---|---|---|---|
| Study 1 | 42.2 ± 11.78 | 42.6 ± 12.39 | — | — | 42.4 ± 12.08 |
| Study 2 | — | — | 42.5 ± 12.44 | 41.6 ± 12.00 | 42.1 ± 12.21 |
| Age, Customized(Participants) | Study 1: Placebo | Study 1: Upadacitinib 15 mg | Study 2: Placebo | Study 2: Upadacitinib 15 mg | Total |
|---|---|---|---|---|---|
| Study 1 — < 40 years | 92 | 87 | — | — | 179 |
| Study 1 — 40 - < 65 years | 108 | 112 | — | — | 220 |
| Study 1 — ≥ 65 years | 9 | 12 | — | — | 21 |
| Study 2 — < 40 years | — | — | 67 | 72 | 139 |
| Study 2 — 40 - < 65 years | — | — | 84 | 81 | 165 |
| Study 2 — ≥ 65 years | — | — | 6 | 3 | 9 |
| Sex: Female, Male(Participants) | Study 1: Placebo | Study 1: Upadacitinib 15 mg | Study 2: Placebo | Study 2: Upadacitinib 15 mg | Total |
|---|---|---|---|---|---|
| Study 1 — Female | 51 | 58 | — | — | 109 |
| Study 1 — Male | 158 | 153 | — | — | 311 |
| Study 2 — Female | — | — | 94 | 89 | 183 |
| Study 2 — Male | — | — | 63 | 67 | 130 |
| Ethnicity (NIH/OMB)(Participants) | Study 1: Placebo | Study 1: Upadacitinib 15 mg | Study 2: Placebo | Study 2: Upadacitinib 15 mg | Total |
|---|---|---|---|---|---|
| Study 1 — Hispanic or Latino | 20 | 17 | — | — | 37 |
| Study 1 — Not Hispanic or Latino | 189 | 194 | — | — | 383 |
| Study 1 — Unknown or Not Reported | 0 | 0 | — | — | 0 |
| Study 2 — Hispanic or Latino | — | — | 15 | 24 | 39 |
| Study 2 — Not Hispanic or Latino | — | — | 142 | 132 | 274 |
| Study 2 — Unknown or Not Reported | — | — | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Study 1: Placebo | Study 1: Upadacitinib 15 mg | Study 2: Placebo | Study 2: Upadacitinib 15 mg | Total |
|---|---|---|---|---|---|
| Study 1 — American Indian or Alaska Native | 0 | 0 | — | — | 0 |
| Study 1 — Asian | 37 | 42 | — | — | 79 |
| Study 1 — Native Hawaiian or Other Pacific Islander | 0 | 0 | — | — | 0 |
| Study 1 — Black or African American | 3 | 1 | — | — | 4 |
| Study 1 — White | 169 | 168 | — | — | 337 |
| Study 1 — More than one race | 0 | 0 | — | — | 0 |
| Study 1 — Unknown or Not Reported | 0 | 0 | — | — | 0 |
| Study 2 — American Indian or Alaska Native | — | — | 0 | 1 | 1 |
| Study 2 — Asian | — | — | 28 | 19 | 47 |
| Study 2 — Native Hawaiian or Other Pacific Islander | — | — | 0 | 0 | 0 |
| Study 2 — Black or African American | — | — | 1 | 2 | 3 |
| Study 2 — White | — | — | 127 | 134 | 261 |
| Study 2 — More than one race | — | — | 1 | 0 | 1 |
| Study 2 — Unknown or Not Reported | — | — | 0 | 0 | 0 |
| Region(Participants) | Study 1: Placebo | Study 1: Upadacitinib 15 mg | Study 2: Placebo | Study 2: Upadacitinib 15 mg | Total |
|---|---|---|---|---|---|
| Study 1 — North America | 25 | 25 | — | — | 50 |
| Study 1 — South/Central America | 14 | 13 | — | — | 27 |
| Study 1 — Western Europe | 25 | 16 | — | — | 41 |
| Study 1 — Eastern Europe | 98 | 109 | — | — | 207 |
| Study 1 — Asia | 34 | 41 | — | — | 75 |
| Study 1 — Other | 13 | 7 | — | — | 20 |
| Study 2 — North America | — | — | 19 | 26 | 45 |
| Study 2 — South/Central America | — | — | 13 | 12 | 25 |
| Study 2 — Western Europe | — | — | 19 | 24 | 43 |
| Study 2 — Eastern Europe | — | — | 72 | 68 | 140 |
| Study 2 — Asia | — | — | 27 | 19 | 46 |
| Study 2 — Other | — | — | 7 | 7 | 14 |
| Time Since AS / nr-axSpA Diagnosis(years) | Study 1: Placebo | Study 1: Upadacitinib 15 mg | Study 2: Placebo | Study 2: Upadacitinib 15 mg | Total |
|---|---|---|---|---|---|
| Study 1 - Duration since AS diagnosis | 7.5 ± 7.51 | 7.9 ± 7.54 | — | — | 7.7 ± 7.52 |
| Study 2 - Duration since nr-axSpA diagnosis | — | — | 4.4 ± 5.83 | 4.5 ± 5.54 | 4.4 ± 5.68 |
| Duration of AS / nr-axSpA Symptoms(years) | Study 1: Placebo | Study 1: Upadacitinib 15 mg | Study 2: Placebo | Study 2: Upadacitinib 15 mg | Total |
|---|---|---|---|---|---|
| Study 1 -Duration of AS symptoms | 12.6 ± 9.29 | 12.9 ± 9.08 | — | — | 12.8 ± 9.18 |
| Study 2 - Duration of nr-axSpA symptoms | — | — | 9.2 ± 8.12 | 9.0 ± 7.86 | 9.1 ± 7.98 |
11 further baseline measures are reported on the registry.
Showing the first 100 of 212 sites across 25 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from Nov 2019 to primary completion in Sep 2021, 21 months.
Results were first posted in Sep 2022, 1 year after primary completion.
Of 20 phase 3 interventional studies under Axial Spondyloarthritis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 39. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Upadacitinib